Stocks and Investing
Stocks and Investing
Fri, October 23, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Charles Duncan Initiated (STOK) at Buy and Held Target at $49 on, Oct 23rd, 2020
Charles Duncan of Cantor Fitzgerald, Initiated "Stoke Therapeutics, Inc." (STOK) at Buy and Held Target at $49 on, Oct 23rd, 2020.
Charles has made no other calls on STOK in the last 4 months.
There is 1 other peer that has a rating on STOK. Out of the 1 peers that are also analyzing STOK, 0 agree with Charles's Rating of Hold.
This is the rating of the analyst that currently disagrees with Charles
- Joseph Stringer of "Needham" Initiated at Strong Buy and Held Target at $42 on, Tuesday, September 29th, 2020
Contributing Sources